• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AnaptysBio (ANAB) Slides As Royalty And Delaware Debate Tests Whether Shares Are A Bargain

    Simply Wall St·10/11/2026 18:21:10
    语音播报

    AnaptysBio (ANAB) has returned to scrutiny after a recent share price slide prompted investors to recheck its royalty-focused biotech model, valuation case, and legal overhang in Delaware.

    The near term mood around AnaptysBio has cooled, with the share price down 5.3% over the past week and 14.7% over 30 days, and that continuing 90 day share price decline of 34.2% suggests momentum has faded even as the 1 year total shareholder return of 119.8% and 3 year total shareholder return of about 2.7x still point to a very strong longer term payoff for investors who held through earlier volatility.

    Compare AnaptysBio's royalty story with other potential value ideas by scanning a curated list of 29 high quality undervalued stocks that also pair solid cash generation with balance sheet strength.

    AnaptysBio now appears to be a solid royalty engine that has experienced a sharp pullback. The business story is strong. The open question is whether the current share price fully reflects that strength or discounts it too aggressively.

    Most Popular Narrative: 49% Undervalued

    AnaptysBio last closed at $45.95 while the most followed narrative pegs fair value closer to $90. This frames the recent selloff as a valuation gap rather than a business collapse.

    Either ANAB wins or settles in the next few months and the stock re-rates toward the high end of the range, or ANAB loses, and you own a 95% margin royalty stream worth $80. You can also sell an OTM covered call if you want to size this a bit bigger.

    See why 3 investors see AnaptysBio as 49% undervalued.

    Result: Fair Value of $90 (UNDERVALUED)

    Still, the AnaptysBio narrative depends heavily on Jemperli royalties and a favorable outcome in Delaware, and setbacks on either front could challenge the bullish case.

    Find out about the key risks to this AnaptysBio narrative.

    Next Steps

    If this AnaptysBio narrative feels divided between promise and concern, consider moving quickly and examining the data yourself so your stance is well grounded. To see both sides presented clearly, start with the 4 key rewards and 3 important warning signs.

    Looking for more AnaptysBio-sized opportunities?

    If AnaptysBio has sharpened your focus, do not stop here. Broaden your watchlist with structured ideas that help you pressure test and upgrade your overall portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.